

Richard M Camicioli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8606801/publications.pdf>

Version: 2024-02-01

175
papers

9,741
citations

36203

51
h-index

43802

91
g-index

183
all docs

183
docs citations

183
times ranked

12436
citing authors

#	ARTICLE	IF	CITATIONS
1	Mediators of cognitive impairment in cerebral amyloid angiopathy. <i>International Journal of Stroke</i> , 2023, 18, 78-84.	2.9	7
2	Diffusion tensor tractography of the fornix in cerebral amyloid angiopathy, mild cognitive impairment and Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2022, 34, 103002.	1.4	2
3	Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy. <i>Neurology</i> , 2022, 98, .	1.5	14
4	Dual-task gait and mild behavioral impairment: The interface between non-cognitive dementia markers. <i>Experimental Gerontology</i> , 2022, 162, 111743.	1.2	10
5	Multi sequence average templates for aging and neurodegenerative disease populations. <i>Scientific Data</i> , 2022, 9, .	2.4	5
6	Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12235.	1.2	6
7	Vascular Contributions to Neurodegeneration: Protocol of the COMPASS-ND Study. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-8.	0.3	6
8	Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1317-1328.	0.4	79
9	Beware of white matter hyperintensities causing systematic errors in FreeSurfer gray matter segmentations!. <i>Human Brain Mapping</i> , 2021, 42, 2734-2745.	1.9	26
10	The role of physical exercise in modulating peripheral inflammatory and neurotrophic biomarkers in older adults: A systematic review and meta-analysis. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111431.	2.2	15
11	White matter hyperintensities mediate the impact of amyloid β on future freezing of gait in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 95-101.	1.1	12
12	New horizons in falls prevention and management for older adults: a global initiative. <i>Age and Ageing</i> , 2021, 50, 1499-1507.	0.7	50
13	Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning. <i>Movement Disorders</i> , 2021, 36, 2144-2155.	2.2	40
14	Subcortical microstructural diffusion changes correlate with gait impairment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 111-118.	1.1	9
15	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. <i>Neurology</i> , 2021, 97, e814-e824.	1.5	14
16	White matter hyperintensities in patients with Parkinson's disease: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2021, 426, 117481.	0.3	19
17	Comprehensive Serum Lipidomics for Detecting Incipient Dementia in Parkinson's Disease. <i>Journal of Proteome Research</i> , 2021, 20, 4053-4067.	1.8	14
18	The Trajectory of Motor Deterioration to Death in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 670567.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Cerebral Amyloid Angiopathy Is Associated With Emotional Dysregulation, Impulse Dyscontrol, and Apathy. <i>Journal of the American Heart Association</i> , 2021, 10, e022089.	1.6	9
20	Evaluation of Clinical Practice Guidelines on Fall Prevention and Management for Older Adults. <i>JAMA Network Open</i> , 2021, 4, e2138911.	2.8	121
21	Falls in Synucleinopathies. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 30-43.	0.3	7
22	Mapping Associations Between Gait Decline and Fall Risk in Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 576-584.	1.3	20
23	The Effects of Music-Contingent Gait Training on Cognition and Mood in Parkinson Disease: A Feasibility Study. <i>Neurorehabilitation and Neural Repair</i> , 2020, 34, 82-92.	1.4	17
24	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1182-1195.	0.4	119
25	Cognitive and motor correlates of grey and white matter pathology in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2020, 27, 102353.	1.4	36
26	CCCDT5 recommendations on early non cognitive markers of dementia: A Canadian consensus. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12068.	1.8	29
27	The associations of the BDNF and APOE polymorphisms, hippocampal subfield volumes, and episodic memory performance across the lifespan. <i>Hippocampus</i> , 2020, 30, 1081-1097.	0.9	4
28	Dual decline in gait speed and cognition is associated with future dementia: evidence for a phenotype. <i>Age and Ageing</i> , 2020, 49, 995-1002.	0.7	32
29	Spectroscopic markers of neurodegeneration in the mesial prefrontal cortex predict survival in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 246-251.	1.1	6
30	Can osmotic demyelination syndrome be a complication of liver failure?. <i>ENeurologicalSci</i> , 2020, 18, 100223.	0.5	2
31	Alzheimer Disease, Biomarkers, and Clinical Symptoms—Quo Vadis?. <i>JAMA Neurology</i> , 2020, 77, 393.	4.5	7
32	Falls in Parkinson's Disease and Lewy Body Dementia. , 2020, , 191-210.		1
33	Falls as a Manifestation of Brain Failure: Gait, Cognition, and the Neurobiology of Falls. , 2020, , 3-20.		3
34	Consensus on Shared Measures of Mobility and Cognition: From the Canadian Consortium on Neurodegeneration in Aging (CCNA). <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 897-909.	1.7	125
35	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 499-511.	0.3	56
36	<p>Orthostatic hypotension and dementia incidence: links and implications</p> <p>Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2181-2194.	1.0	17

#	ARTICLE	IF	CITATIONS
37	Physical Activity and Mobility Differentially Predict Nondemented Executive Function Trajectories: Do Sex and <i>APOE</i> Moderate These Associations?. <i>Gerontology</i> , 2019, 65, 640-648.	1.4	6
38	Gait impairments in Parkinson's disease. <i>Lancet Neurology</i> , The, 2019, 18, 697-708.	4.9	374
39	Management of Cerebral Microbleeds in Clinical Practice. <i>Translational Stroke Research</i> , 2019, 10, 449-457.	2.3	14
40	Progressive Supranuclear Palsy-like Syndrome from Possible Cerebral Amyloid Angiopathy. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 132-136.	0.3	2
41	Cognitive profile of non-demented Parkinson's disease: Meta-analysis of domain and sex-specific deficits. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 32-42.	1.1	26
42	Amygdala subnuclei and healthy cognitive aging. <i>Human Brain Mapping</i> , 2019, 40, 34-52.	1.9	12
43	Frailty Prevalence in the COMPASS-ND Study of Neurodegenerative Disorders. <i>Canadian Geriatrics Journal</i> , 2019, 22, 205-212.	0.7	8
44	Parkinson's disease mild cognitive impairment classifications and neurobehavioral symptoms clarification letter. <i>International Psychogeriatrics</i> , 2018, 30, 1417-1417.	0.6	0
45	The association between lower urinary tract symptoms and falls: Forming a theoretical model for a research agenda. <i>Neurourology and Urodynamics</i> , 2018, 37, 501-509.	0.8	66
46	Vascular Parkinsonism in a Tertiary Care Stroke Prevention Clinic and the Development of a New Screening Strategy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 153-161.	0.7	3
47	Parkinson's disease mild cognitive impairment classifications and neurobehavioral symptoms. <i>International Psychogeriatrics</i> , 2018, 30, 253-260.	0.6	24
48	Nonmotor Symptoms of Parkinsonâ€™s Disease as Predictors of Dementia. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 97-99.	0.3	10
49	Guidelines for Gait Assessments in the Canadian Consortium on Neurodegeneration in Aging (CCNA). <i>Canadian Geriatrics Journal</i> , 2018, 21, 157-165.	0.7	43
50	Alzheimerâ€™s Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 296.	1.7	25
51	Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1401-1416.	1.2	62
52	Differentiating cognitive or motor dimensions associated with the perception of fall-related self-efficacy in Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 26.	2.5	9
53	Cognitive impairment in Parkinsonâ€™s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018, 4, 19.	2.5	110
54	SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment. <i>BMC Geriatrics</i> , 2018, 18, 93.	1.1	45

#	ARTICLE	IF	CITATIONS
55	Utility of the Addenbrooke's Cognitive Examination in Amyotrophic Lateral Sclerosis. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 527-532.	0.3	5
56	Alzheimer's disease: typical and atypical. Part 1. Shodno-Svropeskiy 3/4 urnal Hvorobi Parkinsona J Ekstraparam-dnih Zahvorovan ¹ , 2018, 4, 3-9.	0.0	0
57	Association of Dual-Task Gait With Incident Dementia in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2017, 74, 857.	4.5	263
58	Intensive intervention and cognitive impairment. <i>Neurology</i> , 2017, 88, 1984-1985.	1.5	0
59	Evolution of deep gray matter volume across the human lifespan. <i>Human Brain Mapping</i> , 2017, 38, 3771-3790.	1.9	115
60	Decisional capacity for advanced care directives in Parkinson's disease with cognitive concerns. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 77-79.	1.1	31
61	Regional volumetric change in Parkinson's disease with cognitive decline. <i>Journal of the Neurological Sciences</i> , 2017, 373, 88-94.	0.3	24
62	Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis. <i>Movement Disorders</i> , 2017, 32, 1720-1728.	2.2	69
63	White matter hyperintensity volume predicts persistent cognitive impairment in transient ischemic attack and minor stroke. <i>International Journal of Stroke</i> , 2017, 12, 264-272.	2.9	34
64	Neurological Nuance: Hodgkin lymphoma presenting with Guillain-Barré syndrome. <i>Muscle and Nerve</i> , 2017, 55, 601-604.	1.0	7
65	Alzheimer's Disease Biomarkers Interactively Influence Physical Activity, Mobility, and Cognition Associations in a Non-Demented Aging Population. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 69-86.	1.2	14
66	Concurrent Indicators of Gait Velocity and Variability Are Associated with 25-Year Cognitive Change: A Retrospective Longitudinal Investigation. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 17.	1.7	19
67	Guidelines for Assessment of Gait and Reference Values for Spatiotemporal Gait Parameters in Older Adults: The Biomathics and Canadian Gait Consortiums Initiative. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 353.	1.0	116
68	Early-onset parkinsonism induced by pallidal deep brain stimulation in cervical dystonia. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 140-142.	1.1	3
69	Parkinson Disease: The Relationship Between Non-motor Symptoms and Motor Phenotype. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 261-267.	0.3	46
70	Vascular gait disorders. <i>Neurology</i> , 2016, 86, 1177-1178.	1.5	2
71	Ageing, the Central Nervous System, and Mobility in Older Adults: Interventions. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 1451-1458.	1.7	29
72	Disentangling Cognitive-Frailty: Results From the Gait and Brain Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 1476-1482.	1.7	125

#	ARTICLE	IF	CITATIONS
73	Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging. <i>Journal of the Neurological Sciences</i> , 2016, 361, 87-91.	0.3	17
74	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.4	162
75	Handwriting and pre-frailty in the Lausanne cohort 65+ (Lc65+) study. <i>Archives of Gerontology and Geriatrics</i> , 2015, 61, 8-13.	1.4	15
76	Dopaminergic denervation is not necessary to induce gait disorders in atypical parkinsonian syndrome. <i>Journal of the Neurological Sciences</i> , 2015, 351, 127-132.	0.3	6
77	Physical activity, white matter hyperintensities, and motor function: Bringing out the reserves. <i>Neurology</i> , 2015, 84, 1288-1289.	1.5	3
78	Mobility and Cognition in Seniors. Report from the 2008 Institute of Aging (CIHR) Mobility and Cognition Workshop. <i>Canadian Geriatrics Journal</i> , 2015, 18, 159-167.	0.7	34
79	Response to Letter Regarding Article, "Serial Montreal Cognitive Assessments Demonstrate Reversible Cognitive Impairment in Patients With Acute Transient Ischemic Attack and Minor Stroke" Stroke, 2014, 45, e194.	1.0	0
80	Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 368-374.	2.2	17
81	Motoric cognitive risk syndrome. <i>Neurology</i> , 2014, 83, 718-726.	1.5	345
82	Vitamin D and white matter abnormalities in older adults: a cross-sectional neuroimaging study. <i>European Journal of Neurology</i> , 2014, 21, 1436.	1.7	42
83	Serial Montreal Cognitive Assessments Demonstrate Reversible Cognitive Impairment in Patients With Acute Transient Ischemic Attack and Minor Stroke. <i>Stroke</i> , 2014, 45, 1709-1715.	1.0	72
84	Sleep-related breathing disorders and gait variability: a cross-sectional preliminary study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 140.	0.8	14
85	Reply. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 125-130.	0.6	0
86	Factors Associated with Cognitive Decline in Transient Ischemic Attack Patients. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 303-313.	0.3	4
87	Aging, the Central Nervous System, and Mobility. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013, 68, 1379-1386.	1.7	213
88	Comment: Brain amyloid increases the risk of falls. <i>Neurology</i> , 2013, 81, 441-441.	1.5	3
89	Source memory in normal aging and Parkinson's disease. <i>Journal of Neuropsychology</i> , 2013, 7, 179-192.	0.6	10
90	Neurocognitive Speed and Inconsistency in Parkinson's Disease with and without Incipient Dementia: An 18-Month Prospective Cohort Study. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 764-772.	1.2	21

#	ARTICLE	IF	CITATIONS
91	Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 546-572.	0.6	42
92	Mild cognitive impairment is associated with selected functional markers: Integrating concurrent, longitudinal, and stability effects. <i>Neuropsychology</i> , 2012, 26, 209-223.	1.0	35
93	Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-term Study 1. <i>Movement Disorders</i> , 2012, 27, 1513-1521.	2.2	62
94	Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2012, 79, 1499-1506.	1.5	147
95	Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 809-813.	1.1	74
96	Diffusion tensor imaging of white matter tract evolution over the lifespan. <i>NeuroImage</i> , 2012, 60, 340-352.	2.1	924
97	A reversible cerebral vasoconstriction syndrome. <i>BMJ Case Reports</i> , 2012, 2012, bcr0920114841-bcr0920114841.	0.2	14
98	Survey of Protocols for the Manual Segmentation of the Hippocampus: Preparatory Steps Towards a Joint EADC-ADNI Harmonized Protocol. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 61-75.	1.2	125
99	Structural organization of the prefrontal white matter pathways in the adult and aging brain measured by diffusion tensor imaging. <i>Brain Structure and Function</i> , 2011, 216, 417-431.	1.2	30
100	If amyloid is not in the spinal fluid in Parkinson's disease, where is it and what does it do?. <i>Movement Disorders</i> , 2011, 26, 5-5.	2.2	5
101	Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia. <i>Movement Disorders</i> , 2011, 26, 1443-1450.	2.2	56
102	Metabotropic glutamate receptors-mGluR5-new kid on the dissecting block?. <i>Movement Disorders</i> , 2011, 26, 2479-2479.	2.2	0
103	Othello syndrome at the interface of neurology and psychiatry. <i>Nature Reviews Neurology</i> , 2011, 7, 477-478.	4.9	10
104	Mesial Prefrontal Cortex Degeneration in Amyotrophic Lateral Sclerosis: A High-Field Proton MR Spectroscopy Study. <i>American Journal of Neuroradiology</i> , 2011, 32, 1677-1680.	1.2	18
105	Corpus Callosum and Cingulum Tractography in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 595-600.	0.3	47
106	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2501-2507.	2.2	155
107	Selective effects of aging on brain white matter microstructure: A diffusion tensor imaging tractography study. <i>NeuroImage</i> , 2010, 52, 1190-1201.	2.1	134
108	Relationship between mild cognitive impairment and falls in older people with and without Parkinson's disease: 1-Year Prospective Cohort Study. <i>Gait and Posture</i> , 2010, 32, 87-91.	0.6	88

#	ARTICLE	IF	CITATIONS
109	Dementia Diagnosis. , 2010, , 385-391.		1
110	Circulating Endothelial Progenitor Cells and Age-Related White Matter Changes. Stroke, 2009, 40, 3191-3196.	1.0	37
111	Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Movement Disorders, 2009, 24, 176-182.	2.2	40
112	The course of depressive symptoms in early Parkinson's disease. Movement Disorders, 2009, 24, 1306-1311.	2.2	43
113	Temporal lobe changes in early, untreated Parkinson's disease. Movement Disorders, 2009, 24, 1949-1954.	2.2	67
114	Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. Parkinsonism and Related Disorders, 2009, 15, 187-195.	1.1	82
115	Gaps in patient care practices to prevent hospital-acquired delirium. Canadian Family Physician, 2009, 55, e41-6.	0.1	7
116	Intact presupplementary motor area function in early, untreated Parkinson's disease. Movement Disorders, 2008, 23, 1756-1759.	2.2	5
117	Early, untreated Parkinson's disease patients show reaction time variability. Neuroscience Letters, 2008, 441, 77-80.	1.0	41
118	Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiology of Aging, 2008, 29, 1027-1039.	1.5	146
119	Motor Cortex and Spinal Degeneration in Multisystem Atrophy: A Multimodal Study. Canadian Journal of Neurological Sciences, 2008, 35, 658-660.	0.3	1
120	Aging hippocampus and amygdala. NeuroReport, 2008, 19, 543-547.	0.6	64
121	Review of Handbook of Parkinson's Disease. Fourth Edition. 2007. Edited by Rajesh Pahwa, Kelly E. Lyons. Published by Informa Health Care. 500 pages. Price C\$245.. Canadian Journal of Neurological Sciences, 2008, 35, 687-688.	0.3	0
122	Progressive slowing and gait disorder. , 2008, , 35-38.		0
123	Gait and Balance. , 2007, , 327-342.		1
124	The impact of depressive symptoms in early Parkinson disease. Neurology, 2007, 69, 342-347.	1.5	278
125	Clinical correlates of Lewy-body-related disorders: splitting and lumping or lumping and splitting?. Nature Clinical Practice Neurology, 2007, 3, 308-309.	2.7	0
126	Clinical Trials in Parkinson's Disease Dementia and Dementia with Lewy Bodies. Canadian Journal of Neurological Sciences, 2007, 34, S109-S117.	0.3	7

#	ARTICLE	IF	CITATIONS
127	Axial Signs and Magnetic Resonance Imaging Correlates in Parkinson's Disease. Canadian Journal of Neurological Sciences, 2007, 34, 56-61.	0.3	40
128	Toward a revision of criteria for the dementias. , 2007, 3, 428-440.		15
129	R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Movement Disorders, 2007, 22, 254-256.	2.2	8
130	Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. Movement Disorders, 2007, 22, 382-386.	2.2	42
131	SIMPLE COGNITIVE TESTING (MINI-COG) PREDICTS IN-HOSPITAL DELIRIUM IN THE ELDERLY. Journal of the American Geriatrics Society, 2007, 55, 314-316.	1.3	29
132	DEPRESSIVE SYMPTOMS AND COGNITIVE STATUS AFFECT HEALTH-RELATED QUALITY OF LIFE IN OLDER PATIENTS WITH PARKINSON'S DISEASE. Journal of the American Geriatrics Society, 2007, 55, 1888-1890.	1.3	16
133	Three-dimensional volumetric analysis and reconstruction of amygdala and hippocampal head, body and tail. Psychiatry Research - Neuroimaging, 2007, 155, 155-165.	0.9	110
134	Intraindividual variability in neurocognitive speed: A comparison of Parkinson's disease and normal older adults. Neuropsychologia, 2007, 45, 2499-2507.	0.7	86
135	Gait and posture impairment, parkinsonism and cognitive decline in older people. Journal of Neural Transmission, 2007, 114, 1355-1361.	1.4	40
136	Dual-tasks and walking fast: Relationship to extra-pyramidal signs in advanced Alzheimer disease. Journal of the Neurological Sciences, 2006, 248, 205-209.	0.3	47
137	Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Movement Disorders, 2006, 21, 45-49.	2.2	91
138	Neuroscience, Morality. JAMA - Journal of the American Medical Association, 2006, 295, 2302.	3.8	0
139	Apolipoprotein E ϵ 4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: Relationship to dementia and hallucinations. Movement Disorders, 2005, 20, 989-994.	2.2	55
140	Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology, 2005, 65, 626-628.	1.5	41
141	Corpus Callosum in Neurodegenerative Diseases: Findings in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 345-351.	0.7	47
142	Nature throws curveballs: APOE and nonlinear decline in Alzheimer disease. Neurology, 2005, 65, 1855-1856.	1.5	3
143	Value of an enzymatic assay for the determination of serum ceruloplasmin. Translational Research, 2004, 144, 294-301.	2.4	52
144	Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neuroscience Letters, 2004, 354, 177-180.	1.0	65

#	ARTICLE	IF	CITATIONS
145	Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease. <i>Stroke</i> , 2004, 35, e159-62.	1.0	124
146	Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 7-21.	0.3	24
147	Motor impairment predicts falls in specialized Alzheimer care units. <i>Alzheimer Disease and Associated Disorders</i> , 2004, 18, 214-8.	0.6	50
148	Parkinson's disease is associated with hippocampal atrophy. <i>Movement Disorders</i> , 2003, 18, 784-790.	2.2	294
149	Significant Linkage of Parkinson Disease to Chromosome 2q36-37. <i>American Journal of Human Genetics</i> , 2003, 72, 1053-1057.	2.6	158
150	Independent Predictors of Cognitive Decline in Healthy Elderly Persons. <i>Archives of Neurology</i> , 2002, 59, 601.	4.9	300
151	Parkinsonian syndromes and differential diagnosis. <i>Current Opinion in Neurology</i> , 2002, 15, 461-466.	1.8	12
152	Genome Screen to Identify Susceptibility Genes for Parkinson Disease in a Sample without parkin Mutations. <i>American Journal of Human Genetics</i> , 2002, 71, 124-135.	2.6	162
153	Veering in human locomotion: modulatory effect of attention. <i>Neuroscience Letters</i> , 2002, 331, 175-178.	1.0	17
154	Age at onset of Parkinson disease and apolipoprotein E genotypes. <i>American Journal of Medical Genetics Part A</i> , 2002, 107, 156-161.	2.4	61
155	Identification of parkinsonism and Parkinson's disease. <i>Drugs of Today</i> , 2002, 38, 677.	2.4	6
156	Methylphenidate Increases the Motor Effects of L-Dopa in Parkinson's Disease: A Pilot Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 208-213.	0.2	45
157	Discriminating mild parkinsonism: Methods for epidemiological research. <i>Movement Disorders</i> , 2001, 16, 33-40.	2.2	63
158	Memory Testing in Dementia: How Much Is Enough?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 1-6.	1.2	22
159	Parkinsonism and occupational exposure to pesticides. <i>Occupational and Environmental Medicine</i> , 2001, 58, 582-589.	1.3	74
160	INNOVATIVE INTERGENERATIONAL PREVENTION PROGRAMMING FOR OLDER ADULTS AND ADOLESCENTS. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 105-106.	1.3	2
161	Posterior fossa arachnoid cyst associated with an exertional tremor. <i>Movement Disorders</i> , 2000, 15, 746-749.	2.2	10
162	Dementia in Rural Primary Care Practices in Lake County, Oregon. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2000, 13, 87-92.	1.2	19

#	ARTICLE	IF	CITATIONS
163	A Small 55-Repeat MJD1 CAG Allele in a Patient with Machado-Joseph Disease and Abnormal Eye Movements. <i>European Neurology</i> , 2000, 44, 189-190.	0.6	4
164	Delays in the diagnosis of dementia: Perspectives of family caregivers. , 1999, 14, 20-26.		70
165	Apolipoprotein E ϵ 4 Is Associated with Neuronal Loss in the Substantia nigra in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 437-441.	0.7	8
166	Age-related Brain Changes Associated with Motor Function in Healthy Older People. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 330-334.	1.3	96
167	Diagnosing Dementia: Perspectives of Primary Care Physicians. <i>Gerontologist</i> , The, 1999, 39, 457-464.	2.3	277
168	Analysis of the α -synuclein G209A mutation in familial Parkinson's disease. <i>Lancet</i> , The, 1998, 351, 37-38.	6.3	55
169	Verbal Fluency Task Affects Gait in Parkinson's Disease with Motor Freezing. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 181-185.	1.2	129
170	Balance in the Healthy Elderly. <i>Archives of Neurology</i> , 1997, 54, 976.	4.9	125
171	Cognitive Markers Preceding Alzheimer's Dementia in the Healthy Oldest Old. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 584-589.	1.3	172
172	Neuropsychiatric Adverse Effects of Antiparkinsonian Drugs. <i>Drugs and Aging</i> , 1997, 10, 367-383.	1.3	64
173	An Integrated View of Motor Behavior. <i>The Frontal Lobes and Voluntary Action</i> , by Richard Passingham. 1995. New York: Oxford University Press. 328 pp., \$35.00.. <i>Journal of the International Neuropsychological Society</i> , 1997, 3, 652-654.	1.2	0
174	Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypes. <i>Annals of Neurology</i> , 1997, 42, 655-658.	2.8	52
175	MR imaging of Parkinson's disease with cognitive impairment and dementia. , 0, , 44-56.		0